Clexane

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clexane

Property Description
Active ingredient Enoxaparin Sodium
Form Solution for injection (Pre-filled syringes)
Pharmacological class Low Molecular Weight Heparin (LMWH)
Common purpose Prevention of blood clots (Antithrombotic prophylaxis)
Origin Semi-synthetic (derived from porcine heparin)

What Type of Medicine is Clexane (Enoxaparin Sodium)?

Clexane is a widely clinically recognized prescription-only injectable medicine whose active component is Enoxaparin Sodium. This compound is classified pharmacologically as a Low Molecular Weight Heparin (LMWH) and belongs to the broader category of antithrombotic agents. LMWHs are sophisticated blood thinners designed to interfere specifically with the body’s coagulation cascade, offering a pharmacologically distinct profile compared to older, larger anticoagulant molecules.


Composition, Origin, and Form of Clexane

The core medicinal entity is Enoxaparin Sodium, a semi-synthetic derivative; it is chemically manufactured by depolymerizing naturally sourced heparin, which originates from porcine intestinal mucosa. As a single-ingredient aqueous solution for injection, Clexane is primarily supplied in pre-filled syringes for patient convenience and dosing accuracy. The molecule's complex structure prevents effective absorption if taken orally, requiring delivery via subcutaneous injection to guarantee reliable systemic action.


General Purpose: How Enoxaparin Helps Prevent Blood Clots

The general purpose of this medicine is antithrombotic prophylaxis, which means preventing the formation of unwanted or dangerous blood clots. Enoxaparin works by acting as a targeted blood thinner that selectively binds to a natural plasma protein called Antithrombin-III. This mechanism ensures that the drug primarily inhibits Coagulation Factor Xa, a crucial element in the clotting process, which is the basis for its high efficacy as an anticoagulant. This high selectivity is key to the drug's reliable effectiveness in preventing clot formation in patients at risk for thromboembolic events.

Regulatory References

  1. NIH StatPearls: Enoxaparin

What side effects are possible with Clexane ?

Possible Side Effects and Safety Information

The official safety profile for Clexane (Enoxaparin Sodium) is documented based strictly on regulatory sources like the FDA and EMA. The primary risk documented for this medication is bleeding (hemorrhage), a consequence of its classification as an anticoagulant.

Frequency-Classified Adverse Reactions

Adverse events are categorized by frequency based on clinical trial data:

  • Common (1% to 10%): Hemorrhage, Thrombocytopenia (mild platelet decrease), Thrombocytosis (platelet increase), Anemia, and elevated serum hepatic aminotransferases (liver enzymes). Reactions at the injection site, such as hematoma and pain, are also common.
  • Uncommon (0.1% to 1%): Severe thrombocytopenia and rare skin necrosis at the injection site.

Serious Adverse Reactions

Regulatory documents highlight several serious, less frequent adverse reactions:

  • Major Hemorrhage: Includes life-threatening, fatal, intracranial, and retroperitoneal bleeding.
  • Spinal or Epidural Hematoma: Risk of permanent paralysis, specifically when the medicine is used in conjunction with spinal/epidural puncture procedures.
  • Heparin-Induced Thrombocytopenia (HIT): A severe, immune-mediated decrease in platelet count that must be closely monitored.

Population-Specific Constraints

The official safety documentation specifies areas for increased caution in certain groups:

  • Elderly Patients and individuals with severe renal impairment may have increased systemic exposure to the medicine and are documented to have an elevated risk of bleeding.
  • The multi-dose formulation contains benzyl alcohol, a preservative associated with specific warnings in regulatory texts.

Safety Restrictions

Clexane is strictly contraindicated (should not be used) in patients with active major bleeding, a history of Heparin-Induced Thrombocytopenia (HIT), or known hypersensitivity to enoxaparin sodium, heparin, or pork products (from which the medicine is derived).

Overdose and Emergency Response

Clexane Overdose and When to Seek Help

An overdose of Clexane (enoxaparin sodium), or any low molecular weight heparin, primarily increases the risk of bleeding complications due to its potent anticoagulant effect. The severity of an overdose can range from minor bleeding to life-threatening hemorrhage.

Overdose Symptoms

Clinical signs of a Clexane overdose are typically related to uncontrolled or excessive bleeding, which may include:

  • Unusual bleeding or bruising: Easy bruising, nosebleeds, bleeding gums, or prolonged bleeding from cuts.
  • Internal bleeding signs: Black or bloody stools (melena), blood in urine (hematuria), or coughing up blood.
  • Severe Symptoms (requiring immediate attention): Sudden severe headache, dizziness, weakness, unexplained swelling, or symptoms of paralysis (e.g., tingling, numbness, or loss of function in the legs or back).

Treatment and Seeking Help

In the event of a known or suspected overdose, immediate medical attention is critical. Contact local emergency services (e.g., 911 in the U.S. or equivalent) or a poison control center immediately, even if no symptoms are present. Do not wait for severe bleeding to occur.

Management for significant overdose is generally conducted in a hospital setting. Protamine sulfate is the primary reversal agent (antidote) used to neutralize the anticoagulant effects of enoxaparin. However, protamine sulfate only partially reverses the anti-Factor Xa activity of Clexane. Clinical observation and close monitoring of coagulation parameters, such as anti-Factor Xa levels, are essential to guide the optimal management and dosing of the reversal agent.

Therapeutic Uses of Clexane

Main Uses of Clexane

Clexane (enoxaparin sodium) belongs to a group of medicines known as low molecular weight heparins (LMWH). It is primarily used to prevent and treat blood clots in different parts of the body by thinning the blood and inhibiting the formation of fibrin, a protein involved in the clotting process.

Prevention of Venous Thromboembolism (VTE)

A primary use of this medication is the prevention of blood clots in the veins, particularly in the following circumstances:

  • Surgical Patients: It is often prescribed to individuals undergoing surgery, especially orthopedic procedures like hip or knee replacements, or general surgeries where mobility is restricted.
  • Medical Patients: It is used for people with acute medical illnesses who have limited mobility and are at a higher risk of developing a clot.

Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Clexane is used to treat existing blood clots in the deep veins, usually in the legs (Deep Vein Thrombosis or DVT). It is also used when these clots break away and travel to the lungs, a condition known as Pulmonary Embolism (PE).

Management of Acute Coronary Syndromes

The medication is used to manage certain types of heart-related conditions caused by blood flow interference to the heart muscle. This includes:

  • Unstable Angina: Chest pain that occurs unpredictably or at rest.
  • Acute Myocardial Infarction: Certain types of heart attacks, where it may be used in combination with other medications to keep blood vessels open.

Prevention of Extracorporeal Coagulation

During hemodialysis, Clexane is used to prevent the formation of blood clots in the tubes of the dialysis machine (extracorporeal circulation).


Benefits of Treatment

Clexane offers several clinical benefits for patients at risk of or suffering from thrombotic events:

  • Predictable Activity: Compared to standard unfractionated heparin, it provides a more predictable anticoagulant response.
  • Risk Reduction: Its use significantly reduces the risk of serious complications, such as a pulmonary embolism, which can result from untreated deep vein clots.
  • Outpatient Management: In many cases, it allows for the treatment of certain conditions like DVT at home rather than requiring a prolonged hospital stay.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Population Eligibility for Clexane (Enoxaparin Sodium)

The eligibility for Clexane use is strictly defined by official regulatory authorities, focusing on exclusion criteria and populations requiring conditional use or special monitoring.

Eligibility Domain Official Regulatory Status
Absolute Contraindications Use is prohibited in patients with Active Major Bleeding, a known Hypersensitivity to Enoxaparin or pork products, or recent (≤ 100 days) Heparin-Induced Thrombocytopenia (HIT).
Renal Function Status Patients with Severe Renal Impairment (Creatinine Clearance <30 mL/min) are a restricted group and require use conditional upon dosage adjustment.
Age-Related Status Safety and efficacy have not been established in the general pediatric population (under 18 years). Older adults (75 years) are subject to specific monitoring for increased bleeding risk.
Special Restrictions Use near spinal or epidural anesthesia carries a formal Warning about the risk of serious complications (Spinal/Epidural Hematomas).
Pregnancy/Lactation The multi-dose vial containing Benzyl Alcohol is not recommended for use in pregnant women or neonates. The drug is generally acceptable during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clexane (Enoxaparin Sodium) interactions are primarily documented as pharmacodynamic reinforcement, where co-administration with agents affecting hemostasis significantly increases the documented risk of hemorrhage. Regulatory labeling lists specific contraindicated combinations, such as Defibrotide, due to the risk of synergistic effects. Enoxaparin is also officially designated as not interchangeable with other Low Molecular Weight Heparins or unfractionated heparin.


Documented Interaction Patterns

Interaction Type Interacting Products Official Regulatory Description
Pharmacodynamic Reinforcement Antiplatelet agents (e.g., Aspirin, Clopidogrel), NSAIDs, Thrombolytics Increased risk of hemorrhage due to additive effects on blood clotting.
Substance Interaction Alcohol, certain Herbal Supplements (e.g., Ginkgo) Documented to increase the risk of bleeding.

Administration and Exposure Constraints

The label mandates strict timing requirements for procedures: a separation of 12 to 24 hours is required between the last Enoxaparin dose and neuraxial (spinal/epidural) procedures to mitigate spinal hematoma risk. Furthermore, a population-specific pharmacokinetic alteration is documented for patients with severe renal impairment; their reduced clearance results in a measurable increase in Enoxaparin exposure (AUC).

Mechanism of Action

The Mechanism of Action of Enoxaparin Sodium

The core mechanism of Enoxaparin Sodium involves binding to the natural plasma protein Antithrombin III (AT-III), acting as a catalytic cofactor to enhance AT-III's intrinsic inhibitory power, thereby accelerating the rate at which Antithrombin III neutralizes clotting factors. This molecular action results in a reduction of plasma coagulability.


Targeted Augmentation of Antithrombin III

The drug/AT-III complex primarily targets and neutralizes Activated Coagulation Factor X (Factor Xa). This highly selective inhibition of Factor Xa disrupts the entire downstream coagulation cascade at an early stage, preventing the large-scale generation of Thrombin and reducing the potential for Thrombin generation and subsequent Fibrin formation.


Functional Constraints on Thrombin Neutralization

Due to its molecular size, Enoxaparin demonstrates significantly less capacity to neutralize Factor IIa (Thrombin) compared to its high action against Factor Xa, especially when Thrombin is already bound to a developing clot. This mechanistic limitation defines its primary action as the neutralization of circulating coagulation factors, which suppresses the rate of thrombus formation rather than targeting formed structures.

Dosage and Administration Information

Administration Overview

Clexane is typically administered via subcutaneous injection, which involves delivering the medication into the fatty tissue layer just beneath the skin. This method allows for steady absorption of the active ingredient, enoxaparin sodium, into the bloodstream.

Preparation for Use

The medication is commonly supplied in pre-filled syringes. These syringes are designed for single use and often include an automatic safety system to cover the needle after the injection is complete. Before use, the syringe should be inspected to ensure the liquid is clear and the packaging is intact.

Selection of Injection Sites

Appropriate sites for subcutaneous injection generally include the abdominal area, specifically the lower abdominal wall. It is common practice to rotate the injection site between the left and right sides of the body for each subsequent dose to minimize local tissue irritation. The area chosen should be free from bruising, scarring, or redness.

Handling the Syringe

When preparing the syringe, the protective cap is removed immediately before the injection. Pre-filled syringes may contain a small air bubble; this is a normal feature of the manufacturing process and is not typically expelled before administration, as doing so may result in the loss of medication.

Technique Fundamentals

The injection process involves gently pinching a fold of skin between the thumb and forefinger. The needle is inserted perpendicularly into the skin fold. Throughout the duration of the injection, the skin fold is maintained to ensure the medication is deposited correctly into the subcutaneous tissue. Once the plunger has been fully depressed and the medication delivered, the needle is withdrawn.

Post-Injection Care

Following the removal of the needle, it is advised not to rub the injection site. Rubbing can increase the likelihood of bruising or localized irritation at the point of entry. Used syringes must be disposed of in a puncture-resistant container immediately after use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clexane (Enoxaparin Sodium)


Evidence for VTE Prevention in Surgical and Acutely Ill Medical Patients

Research examining the use of Clexane for preventing blood clots—a process known as prophylaxis—has focused on two major patient groups: those undergoing surgery and those confined to the hospital due to acute illness. For surgical patients, the research includes extensive Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies included adults undergoing major procedures like hip or knee replacements and various general or cancer surgeries. These trials were studied for the occurrence of blood clots, specifically Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as the main outcomes. Studies reported measurements related to the incidence of these clotting events, with some trials comparing Clexane to a placebo or other anticoagulants.

Similar research, often involving controlled trials against placebo, was also evaluated in acutely ill medical patients who have severely limited mobility due to conditions such as acute heart failure or respiratory failure. These studies monitored patients for short periods, typically during their hospitalization, to observe the frequency of VTE events. The research describes patterns in the development of DVT or PE that were measured during the study period. However, the available data for these acutely ill patients primarily covers the short-term window of hospitalization, and there is limited information regarding outcomes observed when treatment was continued beyond the first two weeks in this specific group.


Evidence for the Treatment of Established VTE

Clexane was evaluated in patients who have already been diagnosed with an existing blood clot, such as DVT or PE. The evidence for this indication comes from comparative studies, where Clexane was typically observed alongside Unfractionated Heparin. These trials focused on adults with objectively confirmed clots, including specific patient groups, such as those with active cancer.


Evidence for Use in Acute Coronary Syndromes (Unstable Angina and NSTEMI)

The use of Clexane for Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI) has been explored through large-scale Phase III Randomized Controlled Trials (RCTs). These studies focused on adults experiencing these specific acute coronary syndromes and monitored patients for several weeks. Researchers primarily examined a composite endpoint that typically included death, a subsequent heart attack, or the need for urgent revascularization. Studies report how symptoms evolved in the observed populations during the treatment period, and the rates of this composite endpoint were studied for when Clexane was compared to Unfractionated Heparin.


What Remains Uncertain and Areas of Ongoing Research

The major clinical trials for Clexane primarily involved broad groups of adults. Consequently, data for certain groups remain insufficient, often requiring specific, smaller studies or post-hoc analyses. For instance, research has explored individuals with reduced kidney function, particularly those undergoing hemodialysis. These studies monitor the drug's presence in the blood (anti-Xa levels) to understand the pharmacological patterns measured in this population. The follow-up durations were limited in many key prophylaxis trials, leaving uncertainty about the necessity of VTE prevention beyond short periods for certain medical patients. Comparative evidence against the newest oral anticoagulants in contemporary settings is limited, and research is ongoing to refine optimal protocols.

Key Studies & References

  1. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE
  2. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NICE guideline NG89)

Frequently Asked Questions (FAQ)

Common questions about Clexane (FAQ)

Q: Why is Clexane sometimes called enoxaparin?

A: Enoxaparin Sodium is the generic or non-proprietary chemical name for the active drug component. Clexane is simply one of the brand names under which this medicine is marketed globally. This naming convention is common in the pharmaceutical industry.

Q: What is the difference between Clexane and Lovenox?

A: Regulatory documents confirm that Clexane and Lovenox are simply different brand names used in various countries. They both contain the exact same active ingredient, Enoxaparin Sodium.

Q: Is there a generic version of Clexane available?

A: Yes, the active drug, Enoxaparin Sodium injection, is available under its generic name. It is also marketed under various brand names depending on the region.

Q: How quickly does Clexane start working after I take it?

A: Following a subcutaneous (under-the-skin) injection, the time it takes for the drug to reach its peak effect—the maximum anti-clotting activity—is typically about 4 hours after administration. This measure is based on clinical pharmacokinetics studies.

Q: How long does the effect of Clexane last in the body?

A: The anticoagulant effect of enoxaparin, measured by its anti-Factor Xa activity, is generally detectable in the plasma for approximately 12 hours after a single dose. The body typically eliminates half of the drug over a period of about 3 to 4.5 hours after a single injection.

Q: How long after stopping Clexane can I expect the blood thinning effect to be gone?

A: Regulatory information regarding overdose suggests that if at least 12 hours have passed since the last enoxaparin injection, the anticoagulant effect has generally lessened. In certain situations, this means that the drug's effect may no longer require a specific neutralization treatment.

Q: Is it a problem if the Clexane liquid looks slightly yellow?

A: The liquid medication in the prefilled syringe or vial should be clear and colorless or pale yellow. Official product information advises consulting a healthcare professional if the medicine appears cloudy, is discolored beyond pale yellow, or contains particles.

Q: What are the signs of a serious side effect from Clexane?

A: Signs of serious bleeding can include unusual or excessive bruising, bloody or black stools, blood in the urine, vomiting blood, or a severe headache. Furthermore, signs of a serious spinal clot can include sudden numbness, tingling, leg weakness, or loss of bladder/bowel control. Official sources describe these as signs requiring immediate medical evaluation.

Q: Can Clexane affect my period or menstrual cycle?

A: Since enoxaparin is an anticoagulant (a blood thinner), a possible side effect is increased bleeding. For women who menstruate, this can mean an increased risk of vaginal bleeding or periods that are heavier than usual.

Q: Does Clexane affect blood pressure?

A: The drug’s safety documentation notes that a potential complication following the neutralization of its effect (an action taken in an overdose) is a severe drop in blood pressure (hypotension). Although this is not listed as a common side effect during typical use, it indicates a known link to blood pressure regulation.

Q: Can Clexane be used during pregnancy?

A: Official product information states that enoxaparin is generally considered acceptable for use during pregnancy. However, regulatory warnings specify that preparations containing the preservative benzyl alcohol (such as the multi-dose vial) are not recommended for use in pregnant women. This is a crucial distinction regarding the specific formulation used.

Q: Can I take Clexane if I have a history of ulcers?

A: Regulatory information advises that enoxaparin should be used with caution in patients who have a history of recent gastrointestinal ulceration. This is because a history of ulcers or other conditions that increase the risk of hemorrhage is a factor requiring discussion with a healthcare provider before use.

Q: Do I need to change my diet while taking Clexane?

A: Official documentation indicates that patients should discuss all dietary consumption, including alcohol, with their healthcare provider. This is because alcohol consumption may increase the documented risk of bleeding while taking the medication.

Q: Does Clexane interact with supplements like fish oil or garlic?

A: Official warnings advise patients to discuss all supplements, including those like fish oil (omega-3 fatty acids) and common herbal products, with their provider. This discussion is necessary because many supplements can rarely increase the documented risk of bleeding when combined with an anticoagulant like enoxaparin.

Q: How is Clexane different from Warfarin?

A: Clexane is a Low Molecular Weight Heparin (LMWH) administered by injection and primarily works by targeting and inhibiting Factor Xa. In contrast, Warfarin is an oral anticoagulant that works through a different mechanism by blocking the function of Vitamin K to inhibit the production of several clotting factors.

Q: Why do some people need to take Clexane for many weeks?

A: The necessary duration of treatment is based entirely on the specific medical condition being addressed. While preventive use (prophylaxis) may last only 7–10 days, official indications for treating acute events like deep vein thrombosis (DVT) may require longer periods of therapy. Treatment is generally continued until the patient has achieved clinical stability.

Q: Are there any long-term effects of using Clexane?

A: Studies on the long-term effects of enoxaparin have not been adequately established for all patient populations or uses. As with any anticoagulant, official documents state that the primary long-term risk associated with extended use is bleeding (hemorrhage).

Q: Is it okay to stop Clexane abruptly?

A: The medicine should not be discontinued without consultation with the prescribing healthcare provider, as stopping a blood thinner could lead to harmful or deadly side effects due to blood clot formation.

Q: What kind of studies were done on Clexane use in children?

A: The safety and effectiveness of enoxaparin in the general pediatric population (under 18) are not formally established. However, studies have explored its use in children with doses adjusted according to a specific measure in the blood called anti-Factor Xa concentration.

Q: Is Clexane only used in hospitals?

A: Regulatory indications show that Enoxaparin is approved for use in both inpatient (hospital) and outpatient (home) settings for treating certain conditions. For instance, it is indicated for the treatment of acute deep vein thrombosis in a non-hospitalized setting when used alongside other therapy.

Q: Do studies show that Clexane is effective for home use?

A: The FDA has approved enoxaparin and indicated it for the outpatient treatment of acute deep vein thrombosis without pulmonary embolism. This regulatory approval indicates its established use for outpatient treatment, demonstrating its utility in a non-hospital setting.

Q: Can I travel while I am on Clexane injections?

A: Official medical guidance often references the use of low-molecular-weight heparins like enoxaparin for high-risk travelers. The medicine is sometimes indicated during and immediately following extended travel periods, especially for those with risk factors like severely reduced mobility.

Q: What happens if Clexane is accidentally injected into a muscle?

A: The official labeling specifies that enoxaparin injection is not intended for intramuscular administration (injection into a muscle). The drug is only approved for use via subcutaneous (under the skin) or intravenous (into the vein) injection routes.

Q: Is it necessary to switch from Clexane to another medication before a dental procedure?

A: It is important for dental care providers to be informed that the patient is taking enoxaparin before any procedure is undergone. The provider may then give special instructions regarding the timing of the dose to help manage bleeding risk during the procedure.

How should Clexane be stored and disposed of?

Clexane (enoxaparin sodium) must be stored at room temperature (below 25 C or 77 F) and must be strictly kept from freezing or refrigeration. Syringes should be protected from excess heat, moisture, and direct light, and kept in the original carton until use. It is critical to store the medication in a safe place, out of the sight and reach of children and pets, using a safety-locked cabinet if possible. Prefilled syringes are for single use only. All used syringes and needles must be immediately disposed of in a puncture-proof, hard plastic or metal sharps container. Once the container is full, seal it securely and discard according to local community guidelines for hazardous or medical waste. Do not flush unused or expired medicine down the toilet or throw it in the household trash unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clexane  found in:

A-Z Index: